ANDA 91280, held by Sun Pharm Inds Ltd. Desmopressin Acetate.
As of Nov 16, 2026, ANDA 91280 (Desmopressin Acetate), held by Sun Pharm Inds Ltd, was first approved by FDA on Jan 25, 2013, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 25, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desmopressin Acetate0.004MG/ML · injectable;injection | Desmopressin Acetate | Discontinued |
| Mar 27, 2023 | Supplement 20Labeling · Standard review | Approved | None posted |
| Jan 25, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters